Updated Jul 16, 2026
Rolph Timothy is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $2.67M.
Timothy Rolph is the Chief Scientific Officer at Akero Therapeutics, Inc., a biotechnology company focused on developing therapies for liver diseases. He has been involved in multiple SEC filings related to his role within the company.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-12-09 | AKRO | Akero Therapeutics, Inc. | D — Derivative transaction | 43.8K | — | |
| 2025-12-09 | AKRO | Akero Therapeutics, Inc. | D — Derivative transaction | 238.3K | — | |
| 2025-11-28 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 4.7K | $21.10 | $100K |
| 2025-11-28 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 94.3K | $0.61 | $58K |
| 2025-11-28 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 2.8K | $0.61 | $2K |
| 2025-11-28 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 4.3K | $21.09 | $90K |
| 2025-11-28 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 43.1K | $6.36 | $274K |
| 2025-11-28 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 3.5K | $28.35 | $100K |
| 2025-11-20 | AKRO | Akero Therapeutics, Inc. | G — Bona-fide gift | 37.1K | $0.00 | |
| 2025-10-07 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 1.0K | $46.82 | $49K |
| 2025-10-07 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 11.5K | $46.01 | $527K |
| 2025-10-07 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 12.5K | $28.35 | $354K |
| 2025-09-11 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 553 | $43.02 | $24K |
| 2025-09-08 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 34 | $44.88 | $2K |
| 2025-09-08 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 12.5K | $44.17 | $551K |
| 2025-09-08 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 295 | $28.35 | $8K |
| 2025-09-08 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 5.2K | $6.36 | $33K |
| 2025-09-08 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 7.0K | $21.09 | $149K |
| 2025-08-05 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 7.0K | $49.49 | $345K |
| 2025-08-05 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 5.5K | $49.06 | $272K |
Timothy Rolph is the Chief Scientific Officer at Akero Therapeutics, Inc., a biotechnology company focused on developing therapies for liver diseases. He has been involved in multiple SEC filings related to his role within the company.…
Recorded transactions: 0 open-market purchases () and 13 open-market sales ($2.67M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Rolph Timothy profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.